Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.
OBJECTIVE
A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted.


METHODS
A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months).


RESULTS
Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group.


CONCLUSIONS
Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.
Cano-Parra
J
J
Department of Ophthalmology, La Fe University Hospital, Valencia, Spain.
Diaz-Llopis
M
M
Maldonado
M J
MJ
Vila
E
E
Menezo
J L
JL
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery*; D012008:Recurrence
D016685:Mitomycin